Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
28 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Alios BioPharma, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Alios BioPharma, Inc. - Product Pipeline Review - 2014', provides an overview of the Alios BioPharma, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Alios BioPharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Alios BioPharma, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Alios BioPharma, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Alios BioPharma, Inc.'s pipeline products Reasons to buy - Evaluate Alios BioPharma, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Alios BioPharma, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Alios BioPharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Alios BioPharma, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alios BioPharma, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Alios BioPharma, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Alios BioPharma, Inc. Snapshot 5 Alios BioPharma, Inc. Overview 5 Key Information 5 Key Facts 5 Alios BioPharma, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Alios BioPharma, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Alios BioPharma, Inc. - Pipeline Products Glance 10 Alios BioPharma, Inc. - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Alios BioPharma, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Alios BioPharma, Inc. - Drug Profiles 12 ALS-8176 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 AL-335 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AL-516 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 ALS-8112 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Nucleozin 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecules for Rhinovirus Infections 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Small Molecules to Inhibit RNA-Dependent RNA Polymerase for Influenza 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Small Molecules to Target Viral RNA Polymerase for RSV Infections 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Alios BioPharma, Inc. - Pipeline Analysis 20 Alios BioPharma, Inc. - Pipeline Products by Target 20 Alios BioPharma, Inc. - Pipeline Products by Route of Administration 21 Alios BioPharma, Inc. - Pipeline Products by Molecule Type 22 Alios BioPharma, Inc. - Pipeline Products by Mechanism of Action 23 Alios BioPharma, Inc. - Recent Pipeline Updates 24 Alios BioPharma, Inc. - Dormant Projects 25 Alios BioPharma, Inc. - Locations And Subsidiaries 26 Head Office 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 28 Disclaimer 28
List of Tables Alios BioPharma, Inc., Key Information 5 Alios BioPharma, Inc., Key Facts 5 Alios BioPharma, Inc. - Pipeline by Indication, 2014 7 Alios BioPharma, Inc. - Pipeline by Stage of Development, 2014 8 Alios BioPharma, Inc. - Monotherapy Products in Pipeline, 2014 9 Alios BioPharma, Inc. - Phase II, 2014 10 Alios BioPharma, Inc. - Preclinical, 2014 11 Alios BioPharma, Inc. - Pipeline by Target, 2014 20 Alios BioPharma, Inc. - Pipeline by Route of Administration, 2014 21 Alios BioPharma, Inc. - Pipeline by Molecule Type, 2014 22 Alios BioPharma, Inc. - Pipeline Products by Mechanism of Action, 2014 23 Alios BioPharma, Inc. - Recent Pipeline Updates, 2014 24 Alios BioPharma, Inc. - Dormant Developmental Projects,2014 25
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.